报价延迟最少15分钟:2025/11/15 21:11 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.21 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.48/-1.06
|
|
企业价值
831.32M
|
| 资产负债 |
|
每股账面净值
1.49
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
89.15M
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/15 21:11 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
